Overview

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Status:
Recruiting

Trial end date:
2025-05-10

Target enrollment:

Participant gender:

Summary

This is an early exploratory phase, single arm, non-randomized, open label, treatment study trial to determine the maximum tolerated dose of GC012F injection (CD19-BCMA CAR-T cells) in patients with refractory systemic lupus erythematosus.

Phase:

Early Phase 1

Details

Lead Sponsor:

RenJi Hospital

Collaborator:

Gracell Biotechnology Shanghai Co., Ltd.